Anti-obesity drugs and neural circuits of feeding

被引:80
|
作者
Adan, Roger A. H. [1 ]
Vanderschuren, Louk J. M. J. [1 ]
la Fleur, Susanne E. [1 ]
机构
[1] UMC Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 50 条
  • [21] STRATEGIES AND TACTICS IN USE OF ANTI-OBESITY DRUGS
    BLUNDELL, JE
    LANCET, 1976, 1 (7963): : 804 - 804
  • [22] Novel anti-obesity drugs and plasma lipids
    Nikolic, Dragana
    Toth, Peter P.
    Ferlita, Alessandra
    Di Bartolo, Vittoria
    Montalto, Giuseppe
    Banach, Maciej
    Rizzo, Manfredi
    CLINICAL LIPIDOLOGY, 2014, 9 (02) : 179 - 187
  • [23] Novel anti-obesity drugs for people with HIV
    Chandiwana, Nomathemba
    Manne-Goehler, Jennifer
    Calmy, Alexandra
    Gaayeb, Lobna
    Venter, Willem
    LANCET HIV, 2024, 11 (08): : e502 - e503
  • [24] Anti-obesity drugs: The present and future perspectives
    Lassen, Pierre Bel
    Aron-Wisnewsky, Judith
    CAHIERS DE NUTRITION ET DE DIETETIQUE, 2023, 58 (04): : 273 - 282
  • [25] A short history of serotonergic anti-obesity drugs
    Heal, D. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [26] Do we need anti-obesity drugs?
    Hainer, Vojtech
    Hainerova, Irena Aldhoon
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 8 - 20
  • [27] HOW DO ANTI-OBESITY DRUGS WORK
    TURNER, P
    INTERNATIONAL JOURNAL OF OBESITY, 1978, 2 (03) : 343 - 348
  • [28] Who should pay for anti-obesity drugs?
    Sharma, AM
    NATIONAL MEDICAL JOURNAL OF INDIA, 1999, 12 (02): : 79 - 79
  • [29] Anti-obesity drugs and valvular heart disease
    不详
    DIABETES OBESITY & METABOLISM, 1999, 1 (04): : 255 - 255
  • [30] Anti-obesity drugs: past, present and future
    Rodgers, R. John
    Tschoep, Matthias H.
    Wilding, John P. H.
    DISEASE MODELS & MECHANISMS, 2012, 5 (05) : 621 - 626